#1 Clinical Trials Search in Europe

Corticosteroids, Plain

This article explores the use of corticosteroids in clinical trials, particularly focusing on their role in treating hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. We’ll discuss how corticosteroids are being used alongside other treatments and their potential impact on patient outcomes.

Table of Contents

What are Corticosteroids?

Corticosteroids, also known as CORTICOSTEROIDS, PLAIN, are a class of medications that mimic the effects of hormones your body naturally produces in your adrenal glands[1]. These powerful anti-inflammatory drugs are used to treat a wide variety of conditions, particularly those involving inflammation or immune system responses.

Uses and Benefits

While the clinical trial data provided doesn’t specifically focus on corticosteroids, these medications are widely used in medical practice. Corticosteroids are often prescribed to treat:

  • Inflammatory conditions: Such as arthritis, asthma, and allergic reactions
  • Autoimmune disorders: Including lupus, multiple sclerosis, and inflammatory bowel diseases
  • Certain types of cancer: To reduce inflammation and treat nausea associated with chemotherapy
  • Skin conditions: Like eczema and psoriasis

In the context of cancer treatment, corticosteroids may be used alongside other therapies to manage symptoms and improve quality of life[1].

Administration

According to the provided information, CORTICOSTEROIDS, PLAIN can be administered orally[1]. This means they are taken by mouth, usually in the form of tablets or liquid. The dosage and duration of treatment can vary depending on the specific condition being treated and the individual patient’s needs.

Potential Side Effects

While corticosteroids can be highly effective, they may also cause side effects, especially when used long-term or in high doses. Some potential side effects include:

  • Weight gain
  • Increased appetite
  • Mood changes
  • Increased risk of infections
  • Osteoporosis (weakening of bones)
  • High blood pressure
  • Diabetes or worsening of existing diabetes

It’s important to discuss potential side effects with your healthcare provider before starting treatment[1].

Important Considerations

When taking corticosteroids, there are several important factors to keep in mind:

  1. Do not stop suddenly: If you’ve been taking corticosteroids for more than a few weeks, do not stop taking them abruptly. Your doctor will provide a tapering schedule to gradually reduce your dose.
  2. Follow dosage instructions carefully: Take the medication exactly as prescribed by your healthcare provider.
  3. Inform all healthcare providers: Let any healthcare provider you see know that you are taking corticosteroids.
  4. Regular monitoring: Your doctor may want to monitor you regularly for potential side effects, especially if you’re on long-term treatment.
  5. Dietary considerations: You may need to watch your salt intake and ensure you’re getting enough calcium and vitamin D to protect your bones.

Remember, while this information provides a general overview of corticosteroids, it’s crucial to consult with your healthcare provider for personalized advice and information specific to your medical condition and treatment plan[1].

Aspect Details
Study Type Randomized, Open-label, Phase 3 Study
Main Treatment Sacituzumab Govitecan vs. Treatment of Physician’s Choice
Patient Population HR+/HER2- Metastatic Breast Cancer patients who have received endocrine therapy
Corticosteroid Use Oral administration, likely for supportive care
Primary Endpoint Progression-Free Survival (PFS)
Secondary Endpoints Overall Survival (OS), Objective Response Rate (ORR), Quality of Life measures
Key Eligibility Criteria Age 18+, measurable disease, adequate organ function, prior endocrine therapy
Key Exclusion Criteria Active CNS metastases, significant cardiovascular disease, active infections

FAQ

  • What is the main purpose of using corticosteroids in this clinical trial? In this trial, corticosteroids are not the main focus but are likely used as supportive care. They may help manage side effects from other treatments or alleviate symptoms related to cancer progression.
  • How are corticosteroids administered in this study? The trial information indicates that corticosteroids are administered orally. This means patients take them by mouth, usually in pill or tablet form.
  • Are there any specific eligibility criteria related to corticosteroid use? While there are no specific criteria for corticosteroid use, patients with active chronic inflammatory bowel disease are excluded from the study. This may be related to potential side effects of corticosteroids on the digestive system.
  • Can patients continue their regular corticosteroid medications during the trial? The trial doesn't specifically address this, but patients are generally advised to inform their doctors about all medications they're taking. The use of corticosteroids may be adjusted based on individual patient needs and the trial protocol.
  • What are some potential side effects of corticosteroids in cancer treatment? While not explicitly stated in this trial, common side effects of corticosteroids can include increased appetite, weight gain, mood changes, and increased blood sugar levels. However, these effects can vary depending on the dose and duration of treatment.

Ongoing Clinical Trials on Corticosteroids, Plain

  • Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +5

Glossary

  • Corticosteroids: A class of steroid hormones that are either naturally produced in the body or synthetically manufactured. They are used to reduce inflammation and suppress the immune system in various medical conditions, including cancer treatment.
  • Hormone Receptor-Positive (HR+): A type of breast cancer that has receptors for either estrogen or progesterone hormones. This means the cancer cells may receive signals from these hormones to grow.
  • HER2-Negative: Refers to breast cancer cells that do not have a high amount of a protein called HER2 on their surface. This affects the treatment options and prognosis of the cancer.
  • Metastatic Breast Cancer: Breast cancer that has spread beyond the breast to other parts of the body, such as the bones, liver, lungs, or brain.
  • Endocrine Therapy: A type of cancer treatment that adds, blocks, or removes hormones to slow or stop the growth of hormone-sensitive tumors.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Quality of Life (QoL): A measure of a person's well-being and ability to carry out daily activities, which is often assessed in cancer clinical trials.

References

  1. http://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-with-other-treatments-for-patients-with-hr-her2-metastatic-breast-cancer-after-endocrine-therapy/